<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>生物制药小编 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-20T07:38:48+08:00</updated>
  <subtitle>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>155个GPU！多云场景下的Amber自由能计算</title>
    <updated>2021-01-19T14:32:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/yQX1rNBjIEaOrZ7z-H0-og</id>
    <link href="https://mp.weixin.qq.com/s/yQX1rNBjIEaOrZ7z-H0-og" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>致敬经典，开启新的十年：IL-2/IL-2R简史及药物开发</title>
    <updated>2021-01-19T14:32:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/IcmFu_sCuwkHAYkrz-wT6A</id>
    <link href="https://mp.weixin.qq.com/s/IcmFu_sCuwkHAYkrz-wT6A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>游方和尚专栏 | 大分子生物分析概论（十二）：LBA分析方法的转移</title>
    <updated>2021-01-18T18:28:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/mAx8zsEZunD8kx6mUbxYDQ</id>
    <link href="https://mp.weixin.qq.com/s/mAx8zsEZunD8kx6mUbxYDQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>首批嘉宾阵容揭晓！细胞基因全产业链梳理，精选对话尽在2021年4月TG-Bio</title>
    <updated>2021-01-18T18:28:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/bT-qm2XQZEjOZBmk8dAlWQ</id>
    <link href="https://mp.weixin.qq.com/s/bT-qm2XQZEjOZBmk8dAlWQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Siglec-8  炎症性疾病的新靶点</title>
    <updated>2021-01-17T21:29:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/Cf3JSGI3poRrIQnvW2C1Dg</id>
    <link href="https://mp.weixin.qq.com/s/Cf3JSGI3poRrIQnvW2C1Dg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021最新热点集结！初春领跑细胞基因免疫治疗技术！</title>
    <updated>2021-01-17T21:29:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/ZopEsx-HtQOmYx4WrotaCw</id>
    <link href="https://mp.weixin.qq.com/s/ZopEsx-HtQOmYx4WrotaCw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>克服肿瘤耐药的靶点，选择性抑制剂Selinexor已获批上市</title>
    <updated>2021-01-16T19:35:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/UjJn1AEZJi8PRpdkLiH4lg</id>
    <link href="https://mp.weixin.qq.com/s/UjJn1AEZJi8PRpdkLiH4lg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>纳米抗体商业化的新领域：肿瘤影像诊断</title>
    <updated>2021-01-15T18:32:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/z71CxWaISxXYeTipC5oeng</id>
    <link href="https://mp.weixin.qq.com/s/z71CxWaISxXYeTipC5oeng" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>《治疗用生物制品病毒污染风险控制要点》新书发布| 默克与药品监管部门合作，持续助力中国医药行业</title>
    <updated>2021-01-15T15:43:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/oi5yq1dDiDZl88MfVC4cJA</id>
    <link href="https://mp.weixin.qq.com/s/oi5yq1dDiDZl88MfVC4cJA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗体版PROTAC：AbTAC</title>
    <updated>2021-01-15T15:43:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/IQAxHim7emnXZgAdu8FTlw</id>
    <link href="https://mp.weixin.qq.com/s/IQAxHim7emnXZgAdu8FTlw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>AXL:  新冠病毒进入人体细胞的新受体</title>
    <updated>2021-01-13T19:50:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/wWgJun3-HPqEH9ui5QkFGA</id>
    <link href="https://mp.weixin.qq.com/s/wWgJun3-HPqEH9ui5QkFGA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖达雷妥尤单抗类似药正式获批临床</title>
    <updated>2021-01-13T19:50:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/vThwOxM0_taQfJbNzORcNQ</id>
    <link href="https://mp.weixin.qq.com/s/vThwOxM0_taQfJbNzORcNQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>RNA干扰药物递送方法的简单梳理</title>
    <updated>2021-01-12T17:37:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/VZe6-gHexcHWj-RPMwGNcQ</id>
    <link href="https://mp.weixin.qq.com/s/VZe6-gHexcHWj-RPMwGNcQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>1985-2020年：1149款新药</title>
    <updated>2021-01-12T17:37:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/BzFatgUPRQxneqCIrA5qoA</id>
    <link href="https://mp.weixin.qq.com/s/BzFatgUPRQxneqCIrA5qoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>游方和尚专栏 | 创新药转化医学研究（三）：单抗药物临床前的安全性评价</title>
    <updated>2021-01-11T16:04:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/ZuTMvDo6gxgNkcKEI9Dauw</id>
    <link href="https://mp.weixin.qq.com/s/ZuTMvDo6gxgNkcKEI9Dauw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>线下研讨会(上海) | 抗体药物研发与工艺开发</title>
    <updated>2021-01-11T16:04:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-11:/s/02RdK4WMr3qJEmFUaKA0Pg</id>
    <link href="https://mp.weixin.qq.com/s/02RdK4WMr3qJEmFUaKA0Pg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>老花眼：被忽视的临床需求，匹罗卡品在研药物三期临床成功，有望今年提交上市申请</title>
    <updated>2021-01-10T17:49:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/gVr68cBny1SMZ_WhS9OF2A</id>
    <link href="https://mp.weixin.qq.com/s/gVr68cBny1SMZ_WhS9OF2A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瑞博生物简析</title>
    <updated>2021-01-10T17:49:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/qaYYd5JDAgEL2nYCew2Xlg</id>
    <link href="https://mp.weixin.qq.com/s/qaYYd5JDAgEL2nYCew2Xlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>